Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis & Winston Score

Teva Pharmaceutical Industries makes medicines and sells them to patients, hospitals, and pharmacies around the world. The company is best known for generic drugs — cheaper copies of brand-name medicines that work the same way — and it is one of the largest generic drug makers on the planet. Teva also makes a small number of its own branded medicines, including Austedo for movement disorders and Ajovy for migraines. Teva earns money by selling both generic and branded drugs, with generics making up the majority of its revenue. The company operates globally, with strong businesses in the United States, Europe, and Israel, and it generates roughly $16 billion in annual revenue. Teva carries a heavy debt load from a costly acquisition spree in the 2010s, and it has spent years working to pay that debt down while also settling billions of dollars in opioid-related lawsuits in the U.S. The key question going forward is whether growth from newer branded drugs can offset ongoing price pressure in the highly competitive generics market.